NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF

Nature Medicine

Volumn 13, Issue 1, 2007, Pages 62-69

  Park, Bae Keun ^a   Zhang, Honglai ^a   Zeng, Qinghua ^a   Dai, Jinlu ^b   Keller, Evan T ^b   Giordano, Thomas ^b   Gu, Keni ^c   Shah, Veena ^c   Pei, Lei ^c   Zarbo, Richard J ^c   McCauley, Laurie ^a,b   Shi, Songtao ^d   Chen, Shaoqiong ^a   Wang, Cun Yu ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUTRALIZING ANTIBODY; CD131 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL MATURATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BONE DEVELOPMENT; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MOUSE MUTANT; NORTHERN BLOTTING; PATHOLOGY; RNA INTERFERENCE; WESTERN BLOTTING;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BONE NEOPLASMS; BREAST NEOPLASMS; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846049299     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1519     Document Type: Article

References (46)

1. Roodman, G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664 (2004).
2. Mundy, G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002).
3. Javed, A. et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc. Natl. Acad. Sci. USA 102, 1454-1459 (2005).
4. Kozlow, W. & Guise, T.A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J. Mammary Gland Biol. Neoplasia 10, 169-180 (2005).
5. Zhang, J. et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235-1244 (2001).
6. Martin, T.J. Paracrine regulation of osteoclast formation and activity: milestones in discovery. J. Musculoskelet. Neuronal Interact. 4, 243-253 (2004).
7. Fidler, I.J. Critical determinants of metastasis. Semin. Cancer Biol. 12, 89-96 (2002).
8. Chambers, A.F., Groom, A.C. & MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
9. Huang, S., Pettaway, C.A., Uehara, H., Bucana, C.D. & Fidler, I.J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20, 4188-4197 (2001).
10. Huber, M.A. et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 114, 569-581 (2004).
11. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
12. Guise, T.A. et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98, 1544-1549 (1996).
13. Yin, J.J. et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (1999).
14. Sovak, M.A. et al. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 2952-2960 (1997).
15. Hu, M.C. et al. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237 (2004).
16. Eddy, S.F. et al. Inducible IκB kinase/IκB kinase ε expression is induced by CK2 and promotes aberrant nuclear factor-κB activation in breast cancer cells. Cancer Res. 65, 11375-11383 (2005).
17. Cailleau, R., Young, R., Olive, M. & Reeves, W.J., Jr. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53, 661-674 (1974).
18. Wang, C.-Y., Mayo, M.W. & Baldwin, A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274, 784-787 (1996).
19. Wang, C.-Y., Mayo, M.W., Korneluk, R.C., Goeddel, D.V. & Baldwin, A.S. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683 (1998).
20. Wang, C.-Y., Cusack, J., Liu, R. & Baldwin, A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy via increased apoptosis through inhibition of NF-κB. Nat. Med. 5, 412-417 (1999).
21. Baxter, A. et al. Hit-to-lead studies: the discovery of potent, orally active, thiophene-carboxamide IKK-2 inhibitors. Bioorg. Med. Chem. Lett. 14, 2817-2822 (2004).
22. Mayo, M.W. & Baldwin, A.S. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta 1470, M55-M62 (2000).
23. Greten, F.R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (2004).
24. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11-22 (2004).
25. Yoneda, T. & Hiraga, T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. BioPhys. Res. Commun. 328, 679-687 (2005).
26. Jones, D.H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006).
27. Hamilton, J.A. GM-CSF in inflammation and autoimmunity. Trends Immunol. 23, 403-408 (2002).
28. Hodge, J.M. et al. Osteoclastic potential of human CFU-GM: biophasic effect of GM-CSF. J. Bone Miner. Res. 19, 190-199 (2004).
29. MacDonald, B.R. et al. Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J. Bone Miner. Res. 1, 227-233 (1986).
30. Menaa, C. et al. Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures. J. Clin. Invest. 103, 1605-1613 (1999).
31. Myint, Y.Y. et al. Granulocyte/macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation. Am. J. Pathol. 154, 553-566 (1999).
32. Li, F. et al. Annexin II stimulates RANKL expression through MAPK. J. Bone Miner. Res. 20, 1161-1167 (2005).
33. Coussens, L.M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
34. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000).
35. Clark, E.A., Golub, T.R., Lander, E.S. & Hynes, R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535 (2000).
36. Horak, C.E. & Steeg, P.S. Metastasis gets site specific. Cancer Cell 8, 93-95 (2005).
37. Jimi, E. et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10, 617-624 (2004).
38. Ruocco, M.G. et al. IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201, 1677-1687 (2005).
39. Morgan, H., Tumber, A. & Hill, P.A. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int. J. Cancer 109, 653-660 (2004).
40. Luo, J.L., Maeda, S., Hsu, L.C., Yagita, H. & Karin, M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 6, 297-305 (2004).
41. Queen, M.M., Ryan, R.E., Holzer, R.G., Keller-Peck, C.R. & Jorcyk, C.L. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res. 65, 8896-8904 (2005).
42. Lin, A. & Karin, M. NF-κB in cancer: a marked target. Semin. Cancer Biol. 13, 107-114 (2003).
43. Condeelis, J. & Pollard, J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266 (2006).
44. Li, Q. & Verma, I.M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734 (2002).
45. Chen, Z.J. Ubiquitin signalling in the NF-κB pathway. Nat. Cell Biol. 7, 758-765 (2005).
46. Zeng, Q. et al. Crosstalk between tumor and endothelial cells promotes angiogenesis through MAPK activation of Notch. Cancer Cell 8, 13-23 (2005).